• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Veradermics, Incorporated Common Stock (NY:MANE)

    99.72 -6.35 (-5.99%)
    Official Closing Price Updated: 7:00 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Veradermics, Incorporated Common Stock

    News headline image
    This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
    Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Announces Pricing of Upsized Public Offering and Private Placement
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Announces Launch of Public Offering
    From Veradermics, Incorporated
    Via Business Wire
    These stocks are moving in today's session ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
    From Veradermics, Inc.
    Via Business Wire
    News headline image
    Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics to Participate in Upcoming March Investor Conferences
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
    From Veradermics, Incorporated
    Via Business Wire
    News headline image
    Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
    From Veradermics, Incorporated
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.